Item no. |
HY-108908-25mg |
Manufacturer |
MedChem Express
|
CASRN |
122956-68-7 |
Amount |
25 mg |
Quantity options |
100 mg
10 mM/1 mL
10 mg
1 mg
25 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
98.15 |
Formula |
C34H29ClN6O3 |
Citations |
[1]O'Connor BJ, et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am J Respir Crit Care Med. 1994;150(1):35-40. [2]Alabaster VA, et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions Suppl. 1991;34:221-227. [3]Parry MJ, Alabaster VA, et al. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity. J Lipid Mediat Cell Signal. 1994;10(3):251-268. [4]Guerrero AT, et al. The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia [published correction appears in Naunyn Schmiedebergs Arch Pharmacol. 2013 Apr;386(4):351. Zaperlon, Ana C [corrected to Zarpelon, Ana C]]. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):51-59. [5]Souza DG, et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A. 2009;106(33):14138-14143. |
Smiles |
O=C(C1=C(C2=CC=C(N3C(C)=NC4=C3C=CN=C4)C=C2)NC(C)=C(C(NC5=NC=CC=C5)=O)C1C6=CC=CC=C6Cl)OCC |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
UK-74505 |
Shipping condition |
Room temperature |
Available |
|
Manufacturer - Type |
Reference compound |
Manufacturer - Applications |
COVID-19-immunoregulation |
Manufacturer - Targets |
Dengue virus; Flavivirus |
Shipping Temperature |
Room Temperature |
Storage Conditions |
-20°C, 3 years; 4°C, 2 years (Powder) |
Molecular Weight |
605.09 |
Product Description |
(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection[1][2][3]. |
Manufacturer - Research Area |
Infection; Inflammation/Immunology |
Solubility |
DMSO : 50 mg/mL (ultrasonic) |
Manufacturer - Pathway |
Anti-infection |
Clinical information |
Phase 2 |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.